Multiple myeloma: drivers of discontinuation by treatment line

  • Senín A & al.
  • Ann Hematol
  • 23 ene. 2019

  • de David Reilly
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • In a real-world study of patients with multiple myeloma (MM), response was a key driver of treatment discontinuation in earlier lines of therapy, whereas progressive disease-related death was a more common driver of permanent discontinuation in later lines.
  • The data show significant discrepancies with the results of a large European study, highlighting the need for validation of such studies.

Why this matters

  • Evidence from a European study suggests up to 39% of patients with MM do not receive second-line therapy.

Study design

  • Study to investigate the cause of treatment discontinuation in real-world practice in 108 patients with MM from a hospital in Barcelona.
  • Funding: None disclosed.

Key results

  • All 108 patients received first-line therapy; 32% of these did not receive second-line therapy.
  • Among 73 patients who did receive second-line therapy, 29 did not receive third-line therapy.
  • Achievement of response to therapy was the most common cause of first-line treatment discontinuation (31% of discontinuations); discontinuations for this reason decreased with subsequent treatment lines.
  • 14% of patients discontinued first-line therapy because of progressive disease-related death; discontinuations for this reason increased with subsequent treatment lines.

Limitations

  • Retrospective data.